Search

Community Bulletin: Sarepta Duchenne Pipeline
… in individuals living with Duchenne who are amenable to exon 45 skipping and exon 53 skipping, respectively. SRP-4045  (casimersen) and …
Community Letter: Momentum Trial
… with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Which study does this study hold impact? The …
Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
… for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45 … -- FDA grants Priority Review Status and sets …
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
… in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 … -- Results from the multiple - ascending dose trial …
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
… Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 … -- AMONDYS 45 is Sarepta’s third RNA exon-skipping …
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
… in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 … Results suggest a highly potent next-generation …
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
… Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA … -  …
Community Bulletin: MOMENTUM, Study SRP-5051-201, Update
… in patients with Duchenne Muscular Dystrophy amenable to exon 51-skipping treatment. Part B of MOMENTUM will enroll males with …
Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (MOMENTUM)
… Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (MOMENTUM) …
Our Science
… in the dystrophin gene. Most commonly, one or more exons (parts of the gene) are missing, causing errors in the … enough—or any—working dystrophin protein. The goal of exon skipping, and that of Sarepta’s proprietary technologies, is …